Quoin Pharmaceuticals (NASDAQ:QNRX) Now Covered by Analysts at Craig Hallum

Craig Hallum began coverage on shares of Quoin Pharmaceuticals (NASDAQ:QNRX – Free Report) in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $16.00 price target on the stock.

Other research analysts have also issued research reports about the company. Wall Street Zen lowered Quoin Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, November 15th. Canaccord Genuity Group began coverage on Quoin Pharmaceuticals in a research report on Monday, October 19th. They issued a “buy” rating and a $18.00 price target on the stock. Lake Street Capital started coverage on Quoin Pharmaceuticals in a research report on Wednesday, September 23rd. They set a “buy” rating and a $20.00 price objective for the company. BTIG Research began coverage on Quoin Pharmaceuticals in a report on Monday, October 12th. They issued a “buy” rating and a $14.00 price target for the company. Finally, Weiss Ratings upgraded shares of Quoin Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, November 12th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Quoin Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

View Our Latest Research Report on Quoin Pharmaceuticals

Quoin Pharmaceuticals Stock Performance

NASDAQ:QNRX opened at $3.28 on Friday. The company has a fifty day simple moving average of $4.64 and a two-hundred day simple moving average of $5.67. Quoin Pharmaceuticals has a 52 week low of $3.18 and a 52 week high of $23.50.

Quoin Pharmaceuticals (NASDAQ:QNRX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.52) by $0.55. Equities analysts expect that Quoin Pharmaceuticals will post -7.45 EPS for the current year.

Insider Activity at Quoin Pharmaceuticals

In related news, CFO Sally Lawlor purchased 10,244 shares of Quoin Pharmaceuticals stock in a transaction dated Monday, August 31st. The shares were acquired at an average price of $4.88 per share, with a total value of $49,990.72. Following the completion of the transaction, the chief financial officer owned 10,684 shares of the company’s stock, valued at approximately $52,137.92. This trade represents a 2,328.18% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Myers purchased 20,490 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was purchased at an average price of $4.88 per share, with a total value of $99,991.20. Following the completion of the purchase, the chief executive officer directly owned 37,713 shares of the company’s stock, valued at approximately $184,039.44. This represents a 118.97% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have acquired 57,370 shares of company stock worth $279,966. Company insiders own 7.54% of the company’s stock.

Institutional Trading of Quoin Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC acquired a new position in Quoin Pharmaceuticals during the 3rd quarter valued at approximately $1,077,000. AIGH Capital Management LLC increased its holdings in shares of Quoin Pharmaceuticals by 237.5% in the 3rd quarter. AIGH Capital Management LLC now owns 236,234 shares of the company’s stock worth $1,077,000 after acquiring an additional 166,234 shares during the period. Finally, SummitTX Capital L.P. increased its holdings in shares of Quoin Pharmaceuticals by 54.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after acquiring an additional 35,505 shares during the period. Institutional investors and hedge funds own 8.63% of the company’s stock.

About Quoin Pharmaceuticals

(Get Free Report)

Quoin Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing treatments for rare and orphan diseases, with an emphasis on conditions affecting the skin. Its lead investigational product, QRX003, is a topical therapy being developed for Netherton syndrome, a rare genetic skin disorder. The company has also described plans to explore the treatment’s potential in other skin conditions. QRX003 is investigational and has not been established as a proven treatment.

Read More

Analyst Recommendations for Quoin Pharmaceuticals (NASDAQ:QNRX)

Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.